Idiopathic retroperitoneal fibrosis - Ormond’s disease

Czech version

Authors: M. Průcha ¹; P. Beňo ²; M. Bartůněk ²; J. Votrubová ³; L. Sedláčková ¹; R. Kříž ⁴
Authors‘ workplace: Oddělení klinické biochemie hematologie a imunologie Nemocnice Na Homolce, Praha, přednosta prim. MUDr. Miroslav Průcha, Ph. D. ¹; Chirurgické oddělení Nemocnice Na Homolce, Praha, prim. MUDr. Pavel Beňo ²; Oddělení nukleární medicíny Nemocnice Na Homolce, Praha, přednosta doc. MUDr. Otakar Bělohlávek, CSc. ³; Radiodiagnostické oddělení Nemocnice Na Homolce, Praha, přednostka prim. MUDr. Vladimíra Janoušková, CSc. ⁴
Published in: Vnitř Lék 2008; 54(3): 282-286
Category: Case Reports

Overview

Ormond disease - idiopathic retroperitoneal fibrosis - is a rare condition characterized in situ by the development of fibrous plaques in the retroperitoneal space and anatomicaly dependent structures. The associated encasement of both ureters and progress to hydronefrosis of the kidney are typical clinical manifestations. Less typical manifestations are possible (for example chronic periaortitis), where clinical diagnosis is more difficult. The laboratory findings are not specific for this disease and a biopsy is not always possible for anatomical reasons. In these cases, the use of positron emission tomography/computed tomography - has been found to be the solution, specifically for patients with periaortitis. Ormond disease is generally idiopathic, and secondary - to the use of certain drugs, malignant diseases, infections. Idiopathic retroperitoneal disease is thought to result from the clinical manifestation of a systemic autoimmune disease. The purpose of this article is to present two casuistics, one of a less than usual clinical manifestation. Both positron emission tomography/computed tomography were used in the diagnostics. The treatment of Ormond disease involves the combination of surgical and immunosuppressive treatment.

Key words:
Ormond disease - idiopathic retroperitoneal fibrosis - diagnostics - therapy

Sources

1. Albarran J. Retention renale per peri-ureterite: liberation externe de l’uretere. Assoc Fr Urol 1905; 9: 511-517.

2. Al Musavi D, Mitchenere P, Al-Akraa M. Idiopathic retroperitoneal fibrosis treated with tamoxifen only. Br J Urol 1998; 82: 442-443.

3. Bachmann G, Bauer T, Rau WS. MRT und CT in Diagnose und Verlaufskontrolle der idiopathischen (retroperitonealen) Fibrosen. Radiologie 1995; 35: 200-207.

4. Baker LRI, Mallinson WJW, Gregory MC et al. Idiopathic retroperitoneal fibrosis: a retrospective analysis of 60 cases. Br J Urol 1988; 60: 497-503.

5. Bangard C, Lotz J, Rosenthal H et al. Erdheim-Chester disease versus multifocal fibrosis and Ormond´s disease: a diagnostic dilemma. Clinical Radiology 2004; 59: 1136-1141.

6. Breems DA, Haye H, van der Meulen J The role of advanced atherosclerosis in idiopathic retroperitoneal fibrosis. Analysis of nine cases. Neth J Med 2000; 56: 38-44.

7. Brooks MT, Magill HL, Hanna SL et al. Pediatric case of a day idiopathic retroperitoneal fibrosis. Radio Graphics 1990; 10: 1096-1100.

8. Cogan E, Fastrez R. Azathioprine an alternative treatment for recurrent idiopathic retroperitoneal fibrosis. Arch Intern Med 1985; 145: 753-755.

9. Dvořáček J. The problem of retroperitoneal fibrosis. Rozhl Chir 1975; 54: 467-471.

10. Grotz W, von Zedtwitz I, Andre M et al. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet 1998; 352: 1195.

11. Hughes D, Buckley J. Idiopathic retroperitoneal fibrosis is a macrophage - rich process. Implications for its pathogenesis and treatment. Am J Surg Pathol 1993; 17: 482-490.

12. Jarůšková M, Bělohlávek O. Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states. Eur J Nucl Med 2006; 33: 1-6.

13. Koep L, Zuidema GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977; 81: 250-257.

14. Lepor H, Walsh PC. Idiopathic retroperitoneal fibrosis. J Urol 1979; 122: 1-6.

15. Marcolongo R, Tavolini IM, Laveder F et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004; 116: 194-197.

16. Mathew CV, Shanabo A, Zyka I et al. Retroperitoneal fibrosis with large vessel obstruction, an uncommon vascular disorder. Acta Chirurg Scand 1985; 151: 475-480.

17. Miniberger M, Kašpar M, Drechslerová J et al. Ormondův syndrom (Syndrom retroperitoneální fibrózy). Diagnostické obtíže u necharakteristické formy onemocnění při vyšetření výpočetní tomografií. Čes Radiol 1998; 4: 214-220.

18. Menke DM, Griesse H, Araujo I et al. Inflammatory pseudo-tumors of lymph node origin show macrophage-derived spindle cells and lymphocyte-derived cytokines transcripts without evidence of T cell receptor gene rearrangements. Implications for pathogenesis and classification as an idiopathic retroperitoneal fibrosis-like sclerosing immune reaction. Am J Clin Pathol 1996; 105: 430-439.

19. Neild GH, Justo MR, Wall C et al. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Medicine 2006, 4: 10.1186/741-7015/4/23.

20. Novák I, Morávek P, Baše J et al. Dlouhodobé výsledky léčby nemocných s retroperitoneální fibrózou. Rozhl Chir 1994; 6: 287-290.

21. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 59: 1072-1079.

22. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med1990; 114: 383-387.

23. Piegsa M, Fiegel P. Retroperitonealfibrose. Dtsch Med Wschr1993; 118: 1759-1764.

24. Radoňak J, Vajó J, Toner I et al. Neobvyklá lokalizovaná forma retroperitoneálnej fibrózy. Rozhledy v chirurgii 1999; 78: 378-380.

25. Rasmussen TE, Hallet JW, Metzger RL et al. Genetic risk factors in inflammatory abdominal aortic aneurysma: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element. J Vasc Surg 1997; 25: 356-364.

26. Srinivas V, Dow D. Retroperitoneal fibrosis. Can J Surg 1984; 27: 111-117.

27. Vaglio A, Corradi D, Maneti L et al. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 2003; 114: 454-462.

28. Votrubová J, Fencl P. Hybridní zobrazování PET/CT. Čes Radiol 2004; 56: 333-337.

29. Warnatz K, Keskin AG, Uhl M et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64: 828-833.